Regeneron reports improvement as early as two weeks.1 The published analysis did not find added benefit from combining the antibody with cemdisiran compared with cemdisiran alone.3
What safety requirements come with Livsayis?
The prescribing information carries a Boxed Warning for serious meningococcal infections, along with warnings for other serious infections, particularly those caused by encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae.1 Patients must complete meningococcal vaccination at least two weeks before the first dose, and those who must start sooner also need antibiotics.1
The drug is available only through a Risk Evaluation and Mitigation Strategy program, and patients carry a safety card during treatment and for 12 months after the last dose.1 The most common adverse reactions, occurring in at least 5% of treated patients and more often than with placebo, were injection site reactions, viral infections and urinary tract infections.1
Safety and efficacy in children have not been established.1
Why are more generalized myasthenia gravis treatment options so important?
The disease is rare, chronic and autoimmune, marked by unpredictable and potentially life-threatening muscle weakness.1 In its most common form, abnormal anti-AChR antibodies activate the complement system, including C5, disrupting communication between nerves and muscles.1
Regeneron cites about 85,000 patients in the United States.1 Vu said many patients still have suboptimal control because of waning therapeutic effect, inadequate response or high treatment burden.1
Samantha Masterson, president and CEO of the Myasthenia Gravis Foundation of America, said, “With Livsayis, those living with generalized myasthenia gravis have a new option that may help maintain disease control while reducing the burden treatment can place on daily life.”1
How does cemdisiran work, and what does it mean for Regeneron?
Livsayis degrades the messenger RNA that encodes C5, which blocks production of the protein, lowers circulating levels and inhibits terminal complement activation, a key driver of AChR-positive disease.1
“Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalized myasthenia gravis who need effective disease control without a heavy treatment burden,” said George D. Yancopoulos, M.D., Ph.D., board co-chair, president and chief scientific officer of Regeneron.1
What limitations and open questions remain?
The efficacy data rest on a 24-week primary endpoint, and NIMBLE is ongoing, so durability and long-term safety beyond that window are not established in the materials reviewed.1 The release reports no head-to-head comparison with other approved complement inhibitors, and pricing was not disclosed.
A European Union decision is expected in the second half of 2027, and submissions are planned in additional markets, including Japan.1
Sources
- Livsayis (cemdisiran) approved by the FDA as first and only siRNA therapy in generalized myasthenia gravis and only treatment with four-times-a-year subcutaneous dosing. News release. Regeneron Pharmaceuticals, Inc. November 18, 2026. Accessed November 19, 2026. https://investor.regeneron.com/news-releases/news-release-details/livsayistm-cemdisiran-approved-fda-first-and-only-sirna-therapy
- Cemdisiran regulatory submissions accepted for review by FDA and EMA for the treatment of generalized myasthenia gravis (gMG). News release. Regeneron Pharmaceuticals, Inc. June 22, 2026. Accessed November 19, 2026. https://www.drugs.com/nda/cemdisiran_260622.html
- Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2